Cargando…

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma

BACKGROUND: As a new strategy for advanced lung adenocarcinoma (LUAD), programmed cell death protein 1 (PD-1) pathway inhibitors have been used in clinic for several years. However, the roles of PD-1, programmed cell death-ligand 1 (PD-L1), and CD8A in LUAD are still unclear. In the study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ke, Qiao, Yulei, Wang, Hao, Wang, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729328/
https://www.ncbi.nlm.nih.gov/pubmed/33313223
http://dx.doi.org/10.21037/atm-20-6486
_version_ 1783621433140707328
author Ma, Ke
Qiao, Yulei
Wang, Hao
Wang, Shuai
author_facet Ma, Ke
Qiao, Yulei
Wang, Hao
Wang, Shuai
author_sort Ma, Ke
collection PubMed
description BACKGROUND: As a new strategy for advanced lung adenocarcinoma (LUAD), programmed cell death protein 1 (PD-1) pathway inhibitors have been used in clinic for several years. However, the roles of PD-1, programmed cell death-ligand 1 (PD-L1), and CD8A in LUAD are still unclear. In the study, we aimed to assess the correlation between the mRNA expression of these three factors and the clinical characteristics of LUAD, and to explore the influence of the PD-1/PD-L1/CD8A axis on the prognosis of LUAD. METHODS: The mRNA expression data and clinical characteristics of LUAD patients were retrieved from The Cancer Genome Atlas (TCGA). The optimal cutoff value for PD-1, PD-L1, and CD8A was determined by Cutoff Finder. The chi-square test was used to compare categorical variables. The prognostic effects of variables were analyzed using the Kaplan­­-Meier method and the Cox proportional hazards model. RESULTS: A total of 484 cases were enrolled in this study according to the selection process. The optimal cutoff values for identifying high/low mRNA expression were defined as 27.4 for PD-1, 29.41 for PD-L1, and 95.52 for CD8A. The high expression of PD-1 (P=0.015) and PD-L1 (P=0.027) was more frequent in women than in men. The high expression of PD-1 (P=0.003), PD-L1 (P=0.002), and CD8A (P=0.003) was associated with early T status, whereas CD8A showed a significantly higher expression in both the early stage (P=0.006) and early N stage groups (P=0.031). PD-1, PD-L1, and CD8A were significantly positively correlated among pairs (P<0.001). High expression of each of the three genes was associated with better prognosis (P=0.030 for PD-1, P=0.046 for PD-L1, P=0.019 for CD8A), although the relation did not reach statistical significance in the Cox regression hazards model. CONCLUSIONS: The study defined a group of cutoff values for PD-1, PD-L1, and CD8A to identify high and low mRNA expression in LUAD. The high expression of PD-1, PD-L1, and CD8A was associated with early T status, and CD8A showed significantly higher expression in both early stage and early N stage groups. Although the high expression of each of these three genes was associated with favorable overall survival (OS), they were not independent prognostic factors.
format Online
Article
Text
id pubmed-7729328
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77293282020-12-11 Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma Ma, Ke Qiao, Yulei Wang, Hao Wang, Shuai Ann Transl Med Original Article BACKGROUND: As a new strategy for advanced lung adenocarcinoma (LUAD), programmed cell death protein 1 (PD-1) pathway inhibitors have been used in clinic for several years. However, the roles of PD-1, programmed cell death-ligand 1 (PD-L1), and CD8A in LUAD are still unclear. In the study, we aimed to assess the correlation between the mRNA expression of these three factors and the clinical characteristics of LUAD, and to explore the influence of the PD-1/PD-L1/CD8A axis on the prognosis of LUAD. METHODS: The mRNA expression data and clinical characteristics of LUAD patients were retrieved from The Cancer Genome Atlas (TCGA). The optimal cutoff value for PD-1, PD-L1, and CD8A was determined by Cutoff Finder. The chi-square test was used to compare categorical variables. The prognostic effects of variables were analyzed using the Kaplan­­-Meier method and the Cox proportional hazards model. RESULTS: A total of 484 cases were enrolled in this study according to the selection process. The optimal cutoff values for identifying high/low mRNA expression were defined as 27.4 for PD-1, 29.41 for PD-L1, and 95.52 for CD8A. The high expression of PD-1 (P=0.015) and PD-L1 (P=0.027) was more frequent in women than in men. The high expression of PD-1 (P=0.003), PD-L1 (P=0.002), and CD8A (P=0.003) was associated with early T status, whereas CD8A showed a significantly higher expression in both the early stage (P=0.006) and early N stage groups (P=0.031). PD-1, PD-L1, and CD8A were significantly positively correlated among pairs (P<0.001). High expression of each of the three genes was associated with better prognosis (P=0.030 for PD-1, P=0.046 for PD-L1, P=0.019 for CD8A), although the relation did not reach statistical significance in the Cox regression hazards model. CONCLUSIONS: The study defined a group of cutoff values for PD-1, PD-L1, and CD8A to identify high and low mRNA expression in LUAD. The high expression of PD-1, PD-L1, and CD8A was associated with early T status, and CD8A showed significantly higher expression in both early stage and early N stage groups. Although the high expression of each of these three genes was associated with favorable overall survival (OS), they were not independent prognostic factors. AME Publishing Company 2020-11 /pmc/articles/PMC7729328/ /pubmed/33313223 http://dx.doi.org/10.21037/atm-20-6486 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Ma, Ke
Qiao, Yulei
Wang, Hao
Wang, Shuai
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title_full Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title_fullStr Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title_full_unstemmed Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title_short Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
title_sort comparative expression analysis of pd-1, pd-l1, and cd8a in lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729328/
https://www.ncbi.nlm.nih.gov/pubmed/33313223
http://dx.doi.org/10.21037/atm-20-6486
work_keys_str_mv AT make comparativeexpressionanalysisofpd1pdl1andcd8ainlungadenocarcinoma
AT qiaoyulei comparativeexpressionanalysisofpd1pdl1andcd8ainlungadenocarcinoma
AT wanghao comparativeexpressionanalysisofpd1pdl1andcd8ainlungadenocarcinoma
AT wangshuai comparativeexpressionanalysisofpd1pdl1andcd8ainlungadenocarcinoma